ebola
viru
diseas
evd
one
lethal
transmiss
infect
character
high
fatal
rate
caus
member
filovirida
famili
recent
larg
outbreak
evd
western
africa
highlight
worldwid
threat
repres
diseas
impact
global
public
health
economi
develop
highli
need
antiebola
viru
antivir
far
hamper
shortag
tool
studi
life
cycl
vitro
allow
screen
potenti
activ
compound
outsid
biosafeti
contain
importantli
develop
surrog
model
studi
ebola
viru
entri
set
viral
pseudotyp
ebola
viruslik
particl
tremend
boost
knowledg
viral
life
cycl
identif
promis
antivir
compound
interf
viral
entri
context
combin
surrog
system
largescal
small
molecul
compound
haploid
genet
screen
well
ration
drug
design
drug
repurpos
approach
prove
priceless
quest
develop
treatment
evd
evd
consid
neglect
diseas
caus
small
outbreak
remot
african
villag
ebov
research
focus
mainli
biolog
aspect
viral
infect
prepared
due
potenti
use
bioweapon
limit
laboratori
equip
biosafeti
facil
howev
recent
larg
outbreak
evd
western
africa
character
case
death
highlight
worldwid
danger
diseas
impact
global
public
health
economi
thu
research
molecular
dissect
ebov
life
cycl
receiv
strong
stimulu
financi
support
ultim
goal
develop
effect
prevent
therapeut
approach
review
summar
current
knowledg
specif
step
ebov
life
cycl
entri
process
compound
identifi
far
capabl
interf
well
molecular
model
use
purpos
ebov
envelop
negativestrand
rna
viru
character
virion
nm
diamet
length
rang
hundr
nanomet
micromet
genom
encod
seven
structur
protein
nucleoprotein
n
virion
protein
vp
glycoprotein
gp
rnadepend
rna
polymeras
l
insid
viral
particl
ribonucleoprotein
complex
consist
genom
rna
encapsid
n
bind
l
ribonucleoprotein
complex
interact
envelop
contain
gp
matrix
protein
minor
matrix
protein
viral
tropism
determin
gp
allow
interact
target
cell
ebov
product
infect
broad
rang
cell
type
monocyt
macrophag
dendrit
cell
endotheli
cell
fibroblast
hepatocyt
adren
cortic
cell
follow
host
cell
attach
figur
viru
intern
macropinocytosi
nonselect
process
engulf
bind
target
cell
mediat
differ
attach
factor
ie
ctype
lectin
tcell
immunoglobulin
mucin
domain
tyrosin
kinas
receptor
axl
furthermor
shown
bind
effici
relat
activ
acid
sphingomyelinas
asmas
presenc
plasma
membran
sphingomyelin
viral
side
ebov
attach
entri
mediat
surfac
glycoprotein
gp
class
fusion
protein
nativ
state
gp
triplet
heterodim
compos
receptor
bind
subunit
fusion
subunit
subunit
origin
cleavag
within
golgi
complex
singl
precursor
peptid
remain
associ
disulfid
bond
noncoval
interact
initi
intern
figur
viru
particl
traffick
endolysosom
pathway
end
late
endosom
lowphdepend
cystein
proteas
cathepsin
b
l
process
kda
fusogen
form
expos
put
receptor
bind
domain
subsequ
interact
process
late
endosomallysosom
protein
neimannpick
lead
fusion
viral
envelop
endosom
limit
membran
furthermor
shown
fusion
step
also
requir
twopor
channel
activ
although
specif
role
viral
entri
entir
clear
yet
final
viral
nucleocapsid
releas
cytoplasm
lead
transcript
replic
viral
genom
follow
assembl
bud
viral
progeni
infect
primari
cell
target
viral
progeni
spread
varieti
cell
type
tissu
eventu
result
gener
organ
failur
genu
ebolaviru
filovirida
famili
includ
five
speci
bundibugyo
ebolaviru
reston
ebolaviru
sudan
ebolaviru
tai
forest
ebolaviru
zair
ebolaviru
among
zair
ebolaviru
usual
call
ebola
viru
ebov
main
caus
agent
human
outbreak
caus
ebola
viru
diseas
evd
evd
diseas
human
nonhuman
primat
character
high
fatal
rate
ebov
persist
environ
still
unidentifi
anim
reservoir
like
fruit
bat
maintain
viru
enzoot
cycl
recent
new
ebolaviru
bombali
viru
detect
freetail
bat
sierra
leon
china
new
filoviru
viru
identifi
rousettu
bat
support
role
bat
filoviru
ecolog
occasion
ebov
transmit
nonhuman
primat
duiker
epizoot
cycl
caus
outbreak
high
mortal
human
infect
repres
sporad
event
take
place
context
human
anim
interfac
transmiss
mainli
due
contact
blood
bodi
fluid
infect
human
anim
evd
begin
nonspecif
symptom
involv
fever
fatigu
muscl
ach
evolv
sever
condit
associ
vomit
diarrhea
infrequ
hemorrhag
mental
disord
lead
comatos
state
death
convalesc
phase
survivor
patient
last
sever
month
character
fatigu
joint
pain
well
loss
appetit
memori
viral
rna
detect
specif
organ
testi
one
year
symptom
resolut
virion
intern
macropinocytosi
insid
membranebound
vesicl
gp
cleav
cystein
proteas
activ
fusogen
potenti
cleav
gp
abl
interact
specif
viral
receptor
event
addit
activ
calcium
channel
help
trigger
fusion
viral
envelop
endosomallysosom
membran
lead
viral
genom
releas
follow
transcript
replic
consid
high
lethal
ebov
lack
prophylact
therapeut
treatment
viru
handl
laboratori
contain
thu
worldwid
scientif
institut
conduct
research
test
potenti
countermeasur
use
authent
viru
one
main
challeng
set
studi
focus
character
viral
biolog
pathogenesi
drug
discoveri
overcom
issu
sever
altern
viral
surrog
system
develop
allow
begin
dissect
ebov
entri
pathway
screen
program
identifi
entri
inhibitor
contain
system
includ
viral
pseudotyp
ebovlik
particl
evlp
particular
mani
screen
program
identifi
new
drug
perform
use
pseudotyp
wherea
evlp
system
consid
reliabl
molecularli
dissect
ebov
life
cycl
pseudotyp
viru
viral
vector
display
function
envelop
glycoprotein
heterolog
viru
case
ebovgp
assembl
outer
wrap
thu
acquir
new
tropism
rhabdovirus
retrovirus
like
due
mechan
bud
independ
presenc
envelop
glycoprotein
particularli
suitabl
gener
pseudotyp
end
evlp
gener
presenc
specif
ebov
protein
case
lack
fulli
infecti
viral
genom
system
extens
use
surrog
authent
viru
viral
model
handl
condit
thu
repres
safe
system
identifi
host
factor
virion
intern
macropinocytosi
insid
membranebound
vesicl
gp
cleav
cystein
proteas
activ
fusogen
potenti
cleav
gp
abl
interact
specif
viral
receptor
event
addit
activ
calcium
channel
help
trigger
fusion
viral
envelop
endosomallysosom
membran
lead
viral
genom
releas
follow
transcript
replic
consid
high
lethal
ebov
lack
prophylact
therapeut
treatment
viru
handl
laboratori
contain
thu
worldwid
scientif
institut
conduct
research
test
potenti
countermeasur
use
authent
viru
one
main
challeng
set
studi
focus
character
viral
biolog
pathogenesi
drug
discoveri
overcom
issu
sever
altern
viral
surrog
system
develop
allow
begin
dissect
ebov
entri
pathway
screen
program
identifi
entri
inhibitor
contain
system
includ
viral
pseudotyp
ebovlik
particl
evlp
particular
mani
screen
program
identifi
new
drug
perform
use
pseudotyp
wherea
evlp
system
consid
reliabl
molecularli
dissect
ebov
life
cycl
pseudotyp
viru
viral
vector
display
function
envelop
glycoprotein
heterolog
viru
case
ebovgp
assembl
outer
wrap
thu
acquir
new
tropism
rhabdovirus
retrovirus
like
due
mechan
bud
independ
presenc
envelop
glycoprotein
particularli
suitabl
gener
pseudotyp
end
evlp
gener
presenc
specif
ebov
protein
case
lack
fulli
infecti
viral
genom
system
extens
use
surrog
authent
viru
viral
model
handl
condit
thu
repres
safe
system
identifi
host
factor
involv
viral
entri
well
identifi
valid
new
therapeut
approach
aim
block
viral
entri
final
ebov
surrog
engin
gene
encod
report
protein
use
identif
small
molecul
interf
viral
entri
larg
scale
screen
indiana
vesiculoviru
formerli
name
vesicular
stomat
indiana
viru
vesicular
stomat
viru
vsiv
vsv
follow
indic
vsv
review
member
rhabdovirida
famili
genu
vesiculoviru
vsv
pathogen
viru
livestock
human
infect
rare
event
associ
influenzalik
ill
vsv
handl
laboratori
contain
therefor
use
model
studi
mani
aspect
negativestrand
rna
viral
entri
replic
vsv
assembl
occur
plasma
membran
follow
bud
virion
bullet
shape
nm
per
nm
cell
surfac
bud
vsv
acquir
envelop
consist
lipid
bilay
deriv
plasma
membran
spike
protein
consist
trimer
vsv
glycoprotein
g
vsvg
one
remark
properti
vsv
virion
particularli
select
respect
type
membran
protein
incorpor
viral
envelop
abil
coupl
bud
absenc
glycoprotein
g
led
develop
recombin
virus
vsvgencod
gene
delet
rvsvdeltag
replac
gene
encod
unrel
envelop
protein
replic
compet
rvsvdeltag
differ
strategi
base
replac
vsvgencod
gene
report
gene
gene
encod
fluoresc
protein
green
fluoresc
protein
gfpin
rvsvdeltaggfp
luciferas
viral
stock
gener
provid
produc
cell
envelop
glycoprotein
g
tran
instanc
mean
express
plasmid
figur
glycoprotein
glycoprotein
complex
heterolog
virus
transient
express
cell
transduc
defect
recombin
virus
pseudotyp
particl
effici
releas
supernat
upon
transduct
suscept
cell
rvsvdeltag
pseudotyp
tropism
dictat
heretolog
envelop
glycoprotein
abl
complet
singl
round
replic
express
report
gene
choic
inde
rvsvdeltag
pseudotyp
wide
employ
studi
focus
investig
mechan
ebov
entri
target
cell
screen
antivir
compound
librari
develop
test
aim
identif
neutral
antibodi
vaccin
vector
recent
chen
cowork
report
develop
pseudoviru
infect
mous
model
vivo
pharmacodynam
evalu
filoviru
entri
inhibitor
open
possibl
easili
valid
data
obtain
vitro
experi
variou
heterolog
envelop
alter
tropism
figur
common
exampl
vsvg
pseudotyp
rv
mani
viral
glycoprotein
also
success
use
ebov
lassa
viru
one
highli
pathogen
virus
ebov
pseudotyp
rv
lead
target
transduct
specif
cell
type
allow
studi
viral
entri
mechan
screen
compound
librari
aim
identifi
compound
abl
block
viral
entri
recoveri
growth
pseudotyp
system
base
plasmid
encod
viral
genom
contain
report
gene
gfp
instead
nativ
gene
code
glycoprotein
g
four
plasmid
provid
packag
system
matrix
polymeras
l
phosphoprotein
p
g
begin
cell
cotransfect
plasmid
along
four
packag
plasmid
recov
gcomplement
express
viral
genom
first
viral
rescu
plasmid
encod
rna
polymeras
also
requir
shown
viru
use
gener
pseudotyp
transduc
cell
prevent
transfect
plasmid
encod
heterolog
glycoprotein
pseudotyp
viru
use
transduc
target
cell
recoveri
growth
pseudotyp
system
base
plasmid
encod
viral
genom
contain
report
gene
gfp
instead
nativ
gene
code
glycoprotein
g
four
plasmid
provid
packag
system
matrix
polymeras
l
phosphoprotein
p
g
begin
cell
cotransfect
plasmid
along
four
packag
plasmid
recov
gcomplement
express
viral
genom
first
viral
rescu
plasmid
encod
rna
polymeras
also
requir
shown
viru
use
gener
pseudotyp
transduc
cell
prevent
transfect
plasmid
encod
heterolog
glycoprotein
pseudotyp
viru
use
transduc
target
cell
retrovirus
envelop
rna
virus
replic
dna
intermedi
inde
upon
viral
entri
target
cell
viral
genom
revers
transcrib
doublestrand
dna
transport
cell
nucleu
perman
integr
chromosom
dna
viral
dna
known
provir
dna
replic
cellular
gene
transfer
daughter
cell
provir
dna
transcrib
rna
transport
cytoplasm
translat
structur
enzymat
regulatori
protein
final
new
particl
assembl
incorpor
full
length
genom
rna
bud
cell
membran
matur
trigger
viral
proteas
spheric
matur
viral
particl
around
nm
diamet
abl
infect
new
host
cell
due
abil
integr
genom
chromosom
infect
cell
retroviru
deriv
wide
use
gene
therapi
vector
lentivirus
compar
retrovirus
oncogen
one
display
complex
genom
thu
complex
life
cycl
etiolog
agent
acquir
immunodefici
syndrom
human
immunodefici
viru
hiv
studi
best
character
lentiviru
differ
gammaretrovirus
hiv
effici
infect
rest
termin
differenti
cell
featur
one
main
reason
hivbas
lentivir
vector
current
among
adopt
vector
gene
therapi
differ
human
diseas
last
gener
hiv
lv
highli
improv
term
transgen
deliveri
effici
safeti
furthermor
backbon
rv
easili
manipul
express
intern
marker
gene
order
enabl
identif
transduc
cell
rv
easili
pseudotyp
variou
heterolog
envelop
alter
tropism
figur
common
exampl
vsvg
pseudotyp
rv
mani
viral
glycoprotein
also
success
use
ebov
lassa
viru
one
highli
pathogen
virus
ebov
pseudotyp
rv
lead
target
transduct
specif
cell
type
allow
studi
viral
entri
mechan
screen
compound
librari
aim
identifi
compound
abl
block
viral
entri
along
four
packag
plasmid
recov
gcomplement
express
viral
genom
first
viral
rescu
plasmid
encod
rna
polymeras
also
requir
shown
viru
use
gener
pseudotyp
transduc
cell
prevent
transfect
plasmid
encod
heterolog
glycoprotein
pseudotyp
viru
use
transduc
target
cell
mention
pseudotyp
system
howev
inher
flaw
studi
ebov
entri
due
morpholog
differ
compar
ebov
virion
inde
allud
rvand
vsvpseudotyp
virion
either
spheric
bullet
shape
respect
remark
differ
filament
ebov
particl
overcom
limit
ebovlik
particl
evlp
system
develop
allow
gener
filament
particl
close
resembl
ebov
virion
system
reli
peculiar
properti
ebov
major
matrix
protein
amino
acid
protein
abundantli
express
infect
play
sever
critic
role
viral
life
cycl
particular
essenti
assembl
bud
viral
progeni
support
incorpor
viral
ribonucleocapsid
bud
viru
particl
assembl
either
hexam
appear
involv
bud
octam
function
genom
replic
rna
bind
express
alon
mammalian
cell
promot
format
viruslik
particl
evlp
resembl
filament
virion
alon
abl
initi
bud
evlp
coexpress
np
gp
incorpor
vlp
significantli
enhanc
releas
matur
form
glycoprotein
incorpor
within
evlp
envelop
confer
particl
abil
infect
target
cell
specif
ebov
receptor
thu
evlp
use
studi
pathway
viral
entri
identifi
viral
entri
inhibitor
authent
context
compar
viral
pseudotyp
furthermor
easili
engin
fluoresc
tag
exploit
imagingbas
studi
small
epitop
tag
facilit
detect
without
modifi
bud
capac
incorpor
evlp
one
suitabl
vlp
model
studi
ebov
entri
inhibit
repres
evlp
obtain
express
fuse
frame
betalactamas
enzym
vlp
allow
easili
detect
fusion
step
viral
entri
inde
target
cell
incub
chromogen
betalactamas
substrat
lead
develop
characterist
color
cleav
enzym
sinc
colorimetr
reaction
take
place
immedi
betalactamas
releas
cell
cytosol
upon
fusion
evlp
envelop
endosom
membran
system
allow
distinguish
compound
block
viral
entri
fusion
step
therefor
express
evlp
preciou
tool
investig
mechan
action
activ
molecul
recent
transcriptionand
replicationcompet
evlp
trevlp
develop
allow
studi
almost
aspect
viral
life
cycl
vlp
contain
polycistron
minigenom
encod
report
protein
along
least
viral
protein
gp
figur
trevlp
continu
maintain
transfer
cell
cultur
supernat
infect
transduc
target
cell
target
cell
trevlp
appear
repres
power
experiment
system
screen
small
molecul
librari
lead
identif
molecul
affect
differ
step
viral
replic
addit
entri
one
transcriptionand
replicationcompet
evlp
trevlp
system
base
minigenom
encod
report
gene
viral
protein
gp
case
cotransfect
construct
express
rnp
protein
n
l
insid
produc
cell
drive
format
evlp
harbor
minigenomecontain
nucleocapsid
trevlp
transduc
target
cell
deliv
minigenom
undergo
primari
transcript
mediat
rnp
protein
brought
target
cell
within
trevlp
form
nucleocapsid
result
express
report
gene
target
cell
pretransfect
plasmid
encod
rnp
minigenom
replic
undergo
secondari
transcript
express
report
gene
mediat
rnp
protein
provid
tran
express
construct
furthermor
new
progeni
infecti
trevlp
produc
use
transduc
new
target
cell
classic
approach
develop
antivir
drug
base
identif
compound
affect
function
specif
viral
protein
play
key
role
viral
life
cycl
hand
recent
approach
develop
broadspectrum
antivir
base
target
host
function
essenti
infect
sever
virus
case
step
viral
replic
cycl
target
viral
entri
genom
transcriptionrepl
particl
assembl
releas
particular
viral
entri
essenti
step
establish
infect
thu
repres
attract
target
develop
antivir
compound
date
mani
small
molecul
identifi
inhibitor
ebov
entri
preclin
studi
molecul
newli
identifi
compound
other
alreadi
known
drug
shown
block
ebov
infect
drug
repurpos
program
among
small
molecul
act
ebov
entri
inhibitor
identifi
recent
year
mani
cation
amphiphil
drug
cad
larg
group
chemic
character
hydrophob
aromat
ring
ring
system
hydrophil
sidechain
contain
ioniz
amin
function
group
main
antivir
activ
cad
seem
link
abil
interact
differ
cell
membran
accumul
acid
intracellular
compart
late
transcriptionand
replicationcompet
evlp
trevlp
system
base
minigenom
encod
report
gene
viral
protein
gp
case
cotransfect
construct
express
rnp
protein
n
l
insid
produc
cell
drive
format
evlp
harbor
minigenomecontain
nucleocapsid
trevlp
transduc
target
cell
deliv
minigenom
undergo
primari
transcript
mediat
rnp
protein
brought
target
cell
within
trevlp
form
nucleocapsid
result
express
report
gene
target
cell
pretransfect
plasmid
encod
rnp
minigenom
replic
undergo
secondari
transcript
express
report
gene
mediat
rnp
protein
provid
tran
express
construct
furthermor
new
progeni
infecti
trevlp
produc
use
transduc
new
target
cell
classic
approach
develop
antivir
drug
base
identif
compound
affect
function
specif
viral
protein
play
key
role
viral
life
cycl
hand
recent
approach
develop
broadspectrum
antivir
base
target
host
function
essenti
infect
sever
virus
case
step
viral
replic
cycl
target
viral
entri
genom
transcriptionrepl
particl
assembl
releas
particular
viral
entri
essenti
step
establish
infect
thu
repres
attract
target
develop
antivir
compound
date
mani
small
molecul
identifi
inhibitor
ebov
entri
preclin
studi
molecul
newli
identifi
compound
other
alreadi
known
drug
shown
block
ebov
infect
drug
repurpos
program
among
small
molecul
act
ebov
entri
inhibitor
identifi
recent
year
mani
cation
amphiphil
drug
cad
larg
group
chemic
character
hydrophob
aromat
ring
ring
system
hydrophil
sidechain
contain
ioniz
amin
function
group
main
antivir
activ
cad
seem
link
abil
interact
differ
cell
membran
accumul
acid
intracellular
compart
late
endosomeslysosom
repres
gateway
ebov
entri
host
cell
addit
small
molecul
differ
chemic
structur
antibodi
peptid
act
ebov
entri
inhibitor
affect
viruscel
attach
endocyt
pathway
fusion
step
requir
ebov
product
intern
insid
cell
follow
section
report
main
molecul
identifi
far
ebov
entri
inhibitor
inform
viral
model
use
accomplish
goal
report
appendix
antiarrhythm
drug
amiodaron
dronedaron
verapamil
ion
channel
blocker
shown
inhibit
filoviru
entri
cell
line
primari
cell
use
lentivir
vector
pseudotyp
ebov
marburg
viru
marv
glycoprotein
interestingli
inhibit
viral
entri
effect
concentr
routin
reach
sera
patient
treat
arrhythmia
confirm
use
authent
ebov
furthermor
demonstr
amiodaron
main
metabolit
methyldiethanolamin
show
addit
effect
improv
potenti
efficaci
amiodaron
antiebov
compound
time
addit
experi
suggest
entri
step
target
amiodaron
hostdirect
mechan
action
amiodaron
seem
reduc
viru
bind
target
cell
slow
progress
viral
particl
along
endocyt
pathway
furthermor
drug
act
interf
gp
process
fusion
viral
envelop
endosom
membran
block
viru
particl
insid
vesicl
final
studi
analogu
amiodaron
show
antivir
activ
strictli
correl
drug
abil
accumul
endosom
compart
interfer
endocyt
pathway
despit
promis
result
vitro
encourag
data
mous
model
signific
clinic
improv
report
human
treat
amiodaron
western
african
ebov
epidem
furthermor
recent
report
amiodaron
fail
protect
guinea
pig
lethal
dose
ebov
despit
confirm
antiebov
activ
differ
cell
type
bepridil
calcium
channel
blocker
well
character
antiangin
properti
report
bepridil
strong
vitro
antivir
activ
ebov
inhibit
step
viral
intern
viral
fusion
although
bepridil
may
interfer
calciumsign
requir
endolysosom
fusion
recent
shown
also
directli
interact
ebov
gp
bind
larg
caviti
viral
protein
thu
destabil
prefus
conform
interestingli
bepridil
display
signific
surviv
benefit
surviv
rate
mice
expos
ebov
treat
drug
mgkg
twice
day
begin
day
viru
inocul
recent
dewald
colleagu
confirm
vitro
antivir
activ
bepridil
marv
vero
cell
demonstr
similar
efficaci
surviv
murin
model
marv
diseas
one
latest
discov
ion
channel
inhibitor
activ
earli
phase
ebov
infect
tetrandrin
compound
obtain
plant
stephania
tetrandra
current
employ
tradit
chines
medicin
tetrandrin
block
two
pore
calcium
channel
protein
shown
requir
releas
ebov
genom
target
cell
remark
tetrandrin
show
therapeut
efficaci
mous
model
surviv
rate
roughli
administr
day
challeng
lethal
dose
ebov
despit
primat
studi
requir
human
clinic
trial
begin
tetrandrin
appear
promis
antiebov
prophylact
compound
alon
combin
drug
final
test
myxobacteri
natur
product
librari
beck
cowork
identifi
noricumazol
potassium
channel
inhibitor
new
inhibitor
ebov
entri
chloroquin
drug
wide
use
past
antimalari
therapi
prophylaxi
emerg
resist
plasmodium
spp
strain
drug
readili
avail
well
toler
also
endow
antivir
properti
act
two
level
entri
step
inflamm
process
inde
chloroquin
lysosomotrop
agent
increas
endosom
ph
affect
normal
vesicl
sort
endosomemembran
fusion
furthermor
chloroquin
display
antiinflammatori
properti
downregul
product
cytokin
express
receptor
thu
antivir
activ
chloroquin
could
effect
toward
virus
requir
acid
ph
infect
host
cell
ebov
mitig
clinic
sign
due
deleteri
strong
immun
activ
follow
viral
infect
antiebov
activ
chloroquin
report
sever
vitro
studi
adopt
differ
viral
model
cellular
target
review
despit
promis
evid
vivo
studi
fulli
support
efficaci
chloroquin
treatment
ebov
infect
fact
encourag
result
two
studi
madrid
cowork
show
protect
effect
chloroquin
mice
infect
mouseadapt
ebov
strain
support
recent
data
base
similar
regimen
mice
hamster
guinea
pig
well
cad
chloroquin
may
test
prophylact
treatment
consid
accumul
insid
host
cell
display
antivir
activ
among
drug
correl
chloroquin
amodiaquin
hydroxychloroquin
aminoquinolin
shown
inhibit
filoviru
infect
vitro
use
pseudotyp
viru
assay
authent
ebov
although
vivo
experi
undertaken
yet
promis
result
obtain
retrospect
analysi
perform
patient
treat
liberia
artesunateamodiaquin
western
africa
outbreak
evd
fact
patient
show
lower
risk
death
evd
patient
treat
artemetherlumefantrin
although
observ
lack
sever
control
clinic
effect
artesunateamodiaquin
treatment
better
investig
possibl
therapeut
option
patient
evd
recent
lee
cowork
report
new
antimalari
drug
ferroquin
inhibit
ebov
entri
affect
ph
depend
viral
fusion
step
suramin
drug
adopt
treat
trypanosomecaus
african
blind
demonstr
suramin
competit
inhibitor
heparin
display
antivir
activ
inhibit
chikungunya
viru
ebov
infect
cellular
model
howev
due
signific
side
effect
suramin
taken
consider
therapeut
option
highli
deadli
viral
infect
fdaapprov
compound
emetin
use
treatment
amoebiasi
structur
desmethyl
analog
shown
accumul
endosomelysosom
compart
inhibit
ebov
infect
final
use
vlpbase
approach
anthelmint
drug
albendazol
mebendazol
report
inhibit
ebov
infect
teicoplanin
glycopeptid
antibiot
deriv
potent
inhibit
entri
ebovgppseudotyp
virus
variou
cell
type
studi
antivir
mechan
indic
teicoplanin
block
ebov
entri
specif
inhibit
activ
cathepsin
l
thu
avoid
matur
gp
releas
viral
genom
cytoplasm
antibiot
azithromycin
demonstr
inhibit
evlp
entri
studi
perform
mechan
action
still
larg
uncharacter
among
cad
prove
inhibit
ebov
infect
screen
experi
also
antifung
drug
terconazol
triparanol
formerli
use
cholesterollow
drug
withdrawn
due
numer
toxic
side
effect
chlorpromazin
antipsychot
drug
interfer
ebov
infect
probabl
inhibit
intern
virion
carett
cowork
show
psychoact
drug
imipramin
interfer
entri
ebov
target
cell
similar
effect
report
differ
psychoact
drug
antidepress
drug
sertralin
maprotilin
trimipramin
anticholinerg
benztropin
well
antihistamineantiemet
compound
promethazin
diphenhylpyralin
ketotifen
furthermor
two
old
antihistamin
drug
diphenhydramin
chlorcyclizin
identifi
potenti
candid
repurpos
antiebov
agent
ebov
entri
inhibit
depend
antihistamin
activ
occur
endosom
fact
dock
studi
show
drug
could
directli
bind
ebovgp
interestingli
newer
gener
antihistamin
drug
abl
inhibit
ebov
entri
suggest
gener
antihistamin
good
candid
develop
new
antiebov
compound
remov
unwant
histamin
muscarin
receptor
interact
abil
without
lose
antifiloviru
efficaci
recent
screen
librari
small
molecul
predict
antihistamin
activ
identifi
sever
compound
potent
inhibitori
activ
ebov
infect
data
concern
structureact
relat
prove
extrem
use
find
potenti
scaffold
repres
favor
start
point
rapid
develop
antiebov
therapeut
compound
drug
repurpos
screen
show
sever
select
estrogen
receptor
modul
serm
toremifen
clomiphen
activ
ebov
inhibit
late
stage
viral
entri
target
cell
intriguingli
activ
independ
express
estrogen
receptor
suggest
involv
altern
mode
action
although
exact
inhibitori
mechan
remain
elus
preliminari
experiment
data
suggest
serm
could
interfer
fusion
viral
envelop
endosom
limit
membran
accordingli
shown
toremifen
directli
interact
ebov
gp
trigger
prematur
releas
subunit
thu
prevent
fusion
process
moreov
fan
colleagu
report
serm
reduc
level
cellular
sphingosin
consequ
increas
calcium
insid
endosom
well
accumul
evlp
endosom
furthermor
compound
inhibit
abil
lentivir
vector
pseudotyp
ebov
gp
transduc
target
cell
howev
encourag
vitro
result
conclus
support
anim
studi
mice
one
two
studi
success
confirm
abil
clomiphen
effect
protect
mice
challeng
ebov
case
toremifen
protect
obtain
treat
anim
clearli
addit
investig
possibl
use
differ
anim
model
requir
support
use
serm
antiebov
therapeut
particularli
import
sinc
clomiphen
accumul
eye
male
reproduct
tract
site
ebov
persist
patient
recov
infect
therefor
could
potenti
act
also
ebov
reservoir
thu
reduc
risk
viral
spread
protein
kinas
involv
mani
cellular
pathway
dysregul
associ
diseas
cancer
inde
protein
kinas
inhibitor
alreadi
develop
approv
anticanc
drug
interestingli
also
inhibit
differ
step
life
cycl
sever
virus
ebov
make
except
respect
vivo
experi
demonstr
combin
protein
kinas
inhibitor
sunitinib
erlotinib
protect
mice
challeng
lethal
dose
ebov
haploid
genet
screen
new
approach
identifi
antivir
druggabl
target
discov
cellular
factor
requir
viral
infect
led
identif
ebov
receptor
entri
factor
pikfyv
importantli
pikfyv
activ
pharmacolog
ablat
small
molecul
apilimod
vitro
experi
show
apilimod
inhibit
infect
ebov
marv
primari
macrophag
cell
line
interf
viral
particl
traffick
block
virion
level
earli
endosom
howev
vivo
experi
support
antiebov
efficaci
apilimod
pikfyv
inhibitor
fail
protect
ebovchalleng
mice
perhap
abil
inhibit
interleukin
product
start
notion
ebov
activ
mitogenactiv
protein
kinas
mapk
signal
entri
step
johnson
cowork
report
pyridinyl
imidazol
inhibitor
mapk
inhibit
ebov
infect
cell
line
primari
human
monocytederiv
dendrit
cell
inde
pyridinyl
imidazol
inhibitor
may
repres
lead
develop
effect
drug
treat
ebov
infect
anoth
kinas
potenti
druggabl
antiebov
treatment
cyclin
g
associ
kinas
gak
cellular
regul
clathrinassoci
host
adaptor
protein
gak
regul
intracellular
traffick
multipl
unrel
rna
virus
earli
late
stage
life
cycl
repres
potenti
target
broadspectrum
antivir
recent
optim
isothiazolo
pyridinebas
inhibitor
gak
report
effici
inhibit
vitro
infect
ebov
dengu
chikungunya
virus
final
iodid
inhibitor
eukaryot
elong
factor
kinas
significantli
inhibit
entri
singlecycl
vsv
harbor
ebov
gp
interestingli
antivir
activ
compound
due
activ
kinas
inhibitor
like
lysosomotrop
properti
screen
librari
studi
deriv
small
molecul
identifi
sever
addit
compound
inhibit
ebov
entri
target
cell
differ
mechan
action
basu
cowork
identifi
benzodiazepin
deriv
also
name
compound
well
compound
entri
inhibitor
ebov
sever
compound
antiebov
entri
properti
also
select
screen
analysi
anantpadama
cowork
addit
lead
compound
also
deriv
screen
chines
natur
herb
use
tradit
medicin
iminodyn
inhibitor
gtpase
activ
dynamin
class
protein
involv
scission
newli
form
membran
vesicl
block
ebov
entri
nobiletin
report
affect
traffick
viral
particl
target
pathway
myosin
light
chain
kinas
activ
respect
small
molecul
effect
rang
bacteria
toxin
virus
vitro
vivo
deriv
compound
shown
effect
origin
molecul
effici
inhibit
ebov
infect
vitro
evlp
pseudotyp
virusbas
experi
indic
compound
block
ebov
infect
final
step
viral
entri
level
late
endosom
ebov
infect
block
dyphyllin
deriv
inhibit
vacuolar
h
atpas
avoid
endosom
acidif
use
cystein
cathepsin
inhibitor
antiebov
agent
also
propos
accordingli
recent
studi
show
inhibitor
cathepsinl
nacetyllleucyllleucyl
methion
calpeptin
block
infect
pseudotyp
viru
recent
cui
cowork
report
diarylquinolin
compound
also
activ
entri
inhibitor
ebov
inhibit
fusion
ebov
envelop
endosom
membran
accomplish
specif
peptid
cpeptid
synthet
peptid
correspond
ctermin
heptad
repeat
transmembran
subunit
requir
fusion
shown
cpeptid
combin
argininerich
sequenc
tat
protein
hiv
improv
cellular
uptak
effici
deliv
insid
endosom
block
ebov
infect
interf
membran
fusion
intermedi
recent
li
cowork
report
novel
cyclopeptid
develop
comput
approach
abl
bind
cleavageprim
ebov
gp
exhibit
specif
inhibitori
activ
gppseudotyp
vsv
infect
one
typic
cad
prototyp
cholesterol
synthesi
transport
inhibitor
wide
use
field
lipid
research
efficaci
test
import
human
pathogen
includ
ebov
particular
employ
identif
ebovintracellular
receptor
although
directli
interact
activ
seem
due
pleiotrop
effect
leli
system
continu
reemerg
evd
outbreak
africa
potenti
risk
expans
epidem
contin
well
possibl
use
ebov
bioweapon
make
develop
effect
antiebov
therapeut
one
top
public
health
prioriti
develop
restrict
system
studi
entri
highli
pathogen
virus
outsid
facil
simultan
boost
knowledg
filoviru
entri
identif
potenti
highli
need
antivir
particular
optim
screen
protocol
miniatur
scale
allow
quickli
easili
analyz
larg
librari
small
molecul
thu
provid
array
chemic
structur
model
structur
activ
relationship
studi
addit
integr
sever
model
allow
dissect
step
viral
replic
cycl
affect
drug
candid
shed
light
mechan
action
potenti
new
antivir
although
viral
model
speedup
discoveri
activ
compound
ebov
import
valid
result
use
authent
viru
particular
compound
directli
interact
gp
fact
product
larg
amount
solubl
gp
form
origin
viru
interfer
efficaci
antivir
activ
via
decoy
effect
play
solubl
gp
case
compound
act
host
cell
function
happen
drug
repurpos
approach
undertaken
also
possibl
evalu
multipl
cellular
target
contribut
antivir
efficaci
inform
might
exploit
modifi
molecul
evalu
order
improv
antivir
activ
attenu
potenti
side
effect
consid
high
pathogen
ebov
abil
virus
develop
drug
resist
research
new
molecul
target
differ
viral
host
factor
allow
obtain
effici
antivir
cocktail
context
evid
synerg
effect
drug
combin
report
vitro
vivo
studi
final
intens
activ
last
year
antifilovir
research
may
provid
benefit
neglect
infecti
diseas
lead
discoveri
broad
rang
drug
use
contain
outbreak
caus
viral
agent
vsv
ye
